New Congress and Administration Come to Washington
Members of the 115th Congress were sworn in on January 3rd. There are 7 new Senators, 2 Republicans and 5 democrats, including former California Attorney General Kamala Harris who replaced former Senator Barbara Boxer. The House has 55 new Members, including 28 Republicans and 27 Democrats. 5 are from California, all Democrats: Ro Khanna (District 17, Silicon Valley), Jimmy Panetta (District 20, Central Coast), Salud Carbajal (District 24, Central Coast), Nanette Barragan (District 44, Los Angeles County), and Lou Correa (District 46, Orange County). Speaker Paul Ryan, Majority Leader Kevin McCarthy, Minority Leader Nancy Pelosi, Minority Whip Steny Hoyer were all re-elected to their leadership positions. In the Senate, Mitch McConnell remains Majority Leader, while Chuck Schumer is taking over as Minority Leader.
A new Congress also means new committee assignments for Members. Of notable importance, three California Members, Reps. Raul Ruiz (D-36), Mimi Walters (R-45), and Scott Peters (D-52), have been appointed to the powerful Energy & Commerce Committee, which oversees healthcare matters. We look forward to levering our existing relationships with them as the committee tackles issues important to our industry, such as the reauthorization of FDA user fee agreements, a top priority for Biocom since the current fee funding authority expires in September 2017.
President-elect Donald Trump will be officially sworn in on January 20. Senate nomination hearings to review Trump’s picks for cabinet and other high-level positions are under way. Click here to view the list of nominees. Some of the incoming administration’s priorities include the repeal (and replacement) of the Affordable Care Act (ACA), individual and corporate tax reforms, immigration reform, and an infrastructure package. However, the Trump administration hasn’t issued any specific details yet and hasn’t reached agreements with Congressional leaders on several policies important to our industry, including Medicare reform, drug re-importation, and price transparency, among others. Biocom continues to work with our elected officials to give the California life science community a voice in Washington.
Join Us for our 2017 Oncology DC Fly-In
Building on the successes of our Digital Health Fly-In and Precision Medicine Fly-In these past years, Biocom will host another themed fly-in in 2017, focusing on oncology.
The event will be held from March 20th to 22nd and provide a small group of executives with the unique opportunity to meet with Washington DC regulators and legislators in an intimate setting to directly educate them about oncology and discuss new developments and policy initiatives, as well as issues of concern.
This event is for Biocom members operating in the oncology space. There is no registration fee. Click here for more information. To confirm or discuss your participation, please contact Biocom’s Director of Federal Policy and Government Affairs, Laure Fabrega. Space is limited.